2. Search Result
Search Result
Pathways Recommended: MAPK/ERK Pathway
Results for "

p53 pathway

" in MedChemExpress (MCE) Product Catalog:

55

Inhibitors & Agonists

2

Screening Libraries

5

Peptides

11

Natural
Products

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-19726
    NSC59984
    1 Publications Verification

    		 MDM-2/p53 Cancer
    NSC59984 induces mutant p53 protein degradation via MDM2 and the ubiquitin-proteasome pathway . NSC59984 acts by targeting GOF-mutant p53 and stimulates p73 to restore the p53 pathway signaling .
    NSC59984
  • HY-155974
    MeOIstPyrd

    		MDM-2/p53 Cancer
    MeOIstPyrd is an anti-skin cancer agent. MeOIstPyrd inhibits cell proliferation, migration, and spheroid formation by activating the mitochondrial intrinsic apoptotic pathway. MeOIstPyrd induces DNA damage. MeOIstPyrd activates p53, and increases the half-life of p53 and stabilizes p53 by phosphorylating it at ser15. MeOIstPyrd binds to MDM2 in the p53 sub-pocket and blocks p53-MDM2 interaction .
    MeOIstPyrd
  • HY-19896
    COTI-2
    2 Publications Verification

    		 MDM-2/p53 Apoptosis Cancer
    COTI-2, an anti-cancer agent with low toxicity, is an orally available third generation activator of p53 mutant forms. COTI-2 acts both by reactivating mutant p53 and inhibiting the PI3K/AKT/mTOR pathway. COTI-2 induces apoptosis in multiple human tumor cell lines. COTI-2 exhibits antitumor activity in HNSCC through p53-dependent and -independent mechanisms. COTI-2 converts mutant p53 to wild-type conformation .
    COTI-2
  • HY-123950
    MMRi64

    		MDM-2/p53 Apoptosis Cancer
    MMRi64 disrupts Mdm2-MdmX interactions. MMRi64 downregulates Mdm2 and MdmX in leukemia cells. MMRi64 induces p53 accumulation, and induces the apoptotic arm of the p53 pathway in leukemia/lymphoma cells. MMRi64 can be used for cancer research .
    MMRi64
  • HY-116052
    p53-MDM2-IN-2

    		MDM-2/p53 NF-κB Cancer
    p53-MDM2-IN-2 (Compound 5q) is an orally active p53-MDM2 inhibitor with a Ki value of 0.25 μM. p53-MDM2-IN-2 exerts antitumor activity by inhibiting NF-κB pathway .
    p53-MDM2-IN-2
  • HY-121893
    p53-MDM2-IN-3

    		MDM-2/p53 NF-κB Cancer
    p53-MDM2-IN-3 (Compound 5s) is an orally active p53-MDM2 inhibitor with a Ki value of 0.25 μM. p53-MDM2-IN-3 exerts antitumor activity by inhibiting NF-κB pathway .
    p53-MDM2-IN-3
  • HY-141584
    ATSP-7041

    		MDM-2/p53 Cancer
    ATSP-7041, a selective dual peptide inhibitor of MDM2 and MDMX, effectively reactivates the p53 tumor suppressor pathway in a mechanism-dependent manner in p53-positive cancers .
    ATSP-7041
  • HY-142913
    ABL-L

    		Apoptosis Cancer
    ABL-L induces apoptosis of human laryngocarcinoma cells through p53-dependent pathway.
    ABL-L
  • HY-107466
    WK298

    		MDM-2/p53 Cancer
    WK298 is a potent inhibitor of the MDM2/MDMX-p53 interaction with good anti-tumor activity. WK298 can fully activate the p53 pathway by inhibiting the binding of MDM2 and MDMX to p53. The development of WK298 benefited from a deep understanding of the key elements of the p53-MDM2/MDMX interaction structure .
    WK298
  • HY-18329
    TDP-665759

    		MDM-2/p53 STAT Apoptosis Cancer
    TDP-665759 is an inhibitor for HDm2:p53 complex, and thus activates p53, inhibits STAT3 signaling pathway (EC50 of 5.90 μM) and the cell viability of p53 expressing A549R (IC50 of 7.02 μM). TDP-665759 induces apoptosis in HepG2. TDP-665759 exhibits antitumor efficacy in mouse models .
    TDP-665759
  • HY-13811
    NSC697923
    2 Publications Verification

    		 E1/E2/E3 Enzyme Apoptosis Cancer
    NSC697923 is a potent UBE2N (ubiquitin-conjugating enzyme E2 N, Ubc13) inhibitor. NSC697923 induces neuroblastoma (NB) cell death via promoting nuclear importation of p53 in p53 wild-type NB cells. NSC697923 also induces cell death in p53 mutant NB cells by activation of JNK-mediated apoptotic pathway. NSC697923 inhibits DNA damage and NF-κB signaling. Antitumor activity .
    NSC697923
  • HY-118542
    Nutlin 1

    		MDM-2/p53 Cancer
    Nutlin 1, an antagonist of MDM2, activates a major cellular function of the p53 pathway, with an IC50 value of 0.26 μM .
    Nutlin 1
  • HY-155852
    Lepadin H

    		Ferroptosis Others
    Lepadin H is a marine alkaloid and ferroptosis inducer. Lepadin H exhibits significant cytotoxicity, promotes p53 expression, increases ROS production and lipid peroxidation, decreases SLC7A11 and GPX4 levels, and upregulates ACSL4 expression. Lepadin H induces ferroptosis through the p53-SLC7A11-GPX4 pathway .
    Lepadin H
  • HY-33354
    Nitrochin

    4-NQO

    		 Apoptosis Cancer
    Nitrochin (4-NQO) is a chemical carcinogen. Nitrochin induces oncostatin-M (OSM) in esophageal cells. Nitrochin induces DNA damage, and induces apoptosis via a p53-dependent mitochondrial signaling pathway .
    Nitrochin
  • HY-155851
    Lepadin E

    		Ferroptosis MDM-2/p53 Glutathione Peroxidase Cancer
    Lepadin E is a significantly cytotoxic ferroptosis inducer that induces iron death through the classical p53-SLC7A11-GPX4 pathway. Lepadin E promoted p53 expression, decreases SLC7A11 and GPX4 levels, and leads to increased ROS and lipid peroxide production, and upregulated ACSL4 expression, thus causes cell death. Lepadin E has significant antitumor effect .
    Lepadin E
  • HY-103640
    Amifostine thiol dihydrochloride

    WR-1065 dihydrochloride

    		 MDM-2/p53 Cancer
    Amifostine thiol (WR-1065) dihydrochloride can protect normal tissues from the toxic effects of certain cancer agents and activate p53 through a JNK-dependent signaling pathway.
    Amifostine thiol dihydrochloride
  • HY-P4910
    Baceridin

    		Proteasome Apoptosis Cancer
    Baceridin is a proteasome inhibitor and a cyclic hexapeptide. Baceridin can be isolated from the culture medium of Epiphytic Bacillus. Baceridin can inhibit cell cycle progression and induce tumor cell apoptosis through a p53-independent pathway. Baceridin can be used in cancer research .
    Baceridin
  • HY-N7695
    Physalin B

    		Apoptosis Autophagy Cancer
    Physalin B, one of the major active steroidal constituents of Cape gooseberry, induces cell cycle arrest and triggers apoptosis in breast cancer cells through modulating p53-dependent apoptotic pathway. Physalin B inhibits the ubiquitin-proteasome pathway and induces incomplete autophagic response in human colon cancer cells in vitro .
    Physalin B
  • HY-137864
    Amifostine thiol
    1 Publications Verification

    WR-1065

    		 MDM-2/p53 Cancer
    Amifostine thiol (WR-1065) is an active metabolite of the cytoprotector Amifostine (HY-B0639). Amifostine thiol is a cytoprotective agent with radioprotective abilities. Amifostine thiol activates p53 through a JNK-dependent signaling pathway .
    Amifostine thiol
  • HY-N0292
    Oleuropein
    2 Publications Verification

    		 Cytochrome P450 PPAR Apoptosis Cardiovascular Disease Inflammation/Immunology Cancer
    Oleuropein, found in olive leaves and oil, exerts antioxidant, anti-inflammatory and anti-atherogenic effects through direct inhibition of PPARγ transcriptional activity . Oleuropein induces apoptosis in breast cancer cells via the p53-dependent pathway and through the regulation of Bax and Bcl2 genes. Oleuropein also inhibits aromatase .
    Oleuropein
  • HY-N7496
    Odoroside A

    		Apoptosis Cancer
    Odoroside A is an active ingredient extracted from the leaves of Nerium oleander Linn. Odoroside A has anti-cancer activity. Odoroside A could induce apoptosis and cell cycle arrest through ROS/p53 signaling pathway, leading to the tumor cell death .
    Odoroside A
  • HY-116794
    SF5

    2,2-Diphenylethyl isothiocyanate

    		 Apoptosis JNK MDM-2/p53 Caspase Cancer
    SF5 (2,2-Diphenylethyl isothiocyanate) is a sulforaphane analog. SF5 inhibits apoptosis by the JNK-p53-caspase pathway. SF5 can be used as a new renal protective agent for drug-resistant acute renal disease .
    SF5
  • HY-118375
    Phenylbutyl isoselenocyanate

    ISC-4

    		 Apoptosis Cancer
    Phenylbutyl isoselenocyanate (ISC-4) is a selective apoptosis inducer that increases reactive oxygen species levels to inhibit androgen receptor (AR) and activate p53 pathway. Phenylbutyl isoselenocyanate induces apoptosis in LNCaP prostate cancer cells and has anti-prostate cancer properties.
    Phenylbutyl isoselenocyanate
  • HY-119666
    Rooperol

    		Apoptosis Reactive Oxygen Species MDM-2/p53 Oct3/4 Inflammation/Immunology Cancer
    Rooperol is a norlignan analog with antitumor, anti-inflammatory, and antioxidant activities. Rooperol induces apoptosis in CSCs through a mitochondrial-induced increase in ROS and a p53-dependent pathway, while also downregulating the expression of key stem cell regulatory factors, such as Oct4, Nanog, and Sox2, ultimately exerting its anticancer effects .
    Rooperol
  • HY-103640R
    Amifostine thiol dihydrochloride (Standard)

    		MDM-2/p53 Cancer
    Amifostine thiol (dihydrochloride) (Standard) is the analytical standard of Amifostine thiol (dihydrochloride). This product is intended for research and analytical applications. Amifostine thiol (WR-1065) dihydrochloride can protect normal tissues from the toxic effects of certain cancer agents and activate p53 through a JNK-dependent signaling pathway.
    Amifostine thiol dihydrochloride (Standard)
  • HY-149306
    MS78

    		Histone Acetyltransferase MDM-2/p53 Cancer
    MS78 is an acetylation targeting chimera (AceTAC) that acetylates the p53 tumor suppressor protein. MS78 recruits histone acetyltransferase p300/CBP to acetylate the p53Y220C mutant. MS78 upregulates TRAIL apoptotic genes and downregulates DNA damage response pathways. MS78 contains a CBP/p300 binder, a p53Y220C binder and a linker .
    MS78
  • HY-124896
    Bonannione A

    6-Geranylnaringenin; Mimulone

    		 Phosphatase Apoptosis Autophagy Inflammation/Immunology Cancer
    Bonannione A (6-Geranylnaringenin; Mimulone), a prenylflavonoid, is an orally active and potent protein tyrosine phosphatase 1B (PTP1B) inhibitor with an IC50 of 14 µM. Bonannione A triggers caspase-dependent apoptosis. Bonannione A induces autophagy through p53-mediated AMPK/mTOR pathway. Bonannione A shows anti-inflammatory, antiradical and anti-cancer activity .
    Bonannione A
  • HY-108521
    HX531

    		RAR/RXR Apoptosis Metabolic Disease Cancer
    HX531 is an effective RXR antagonist with oral activity, with an IC50 of 18 nM, with activity against black melanoma. HC531 can eliminate the anti-apoptotic effects of all-trans-retinoic acid (t-RA) and exerts anti-obesity and anti-diabetic effects through leptin-dependent pathways and the p53-p21Cip1 pathway, resulting in G0/G1 cell cycle arrest .
    HX531
  • HY-155532
    10m/ZS44

    		Apoptosis Cancer
    10m/ZS44 is a blood-brain barrier-permeable Glioblastoma (GBM) inhibitor. 10m/ZS44 significantly inhibits GBM tumor growth in a mouse xenograft model. 10m/ZS44 also activates the SIRT1/p53-mediated apoptosis pathway, thereby inhibiting the proliferation of U251 cells .
    10m/ZS44
  • HY-158210
    Wnt/β-catenin-IN-3

    		Wnt β-catenin MDM-2/p53 Cancer
    Wnt/β-catenin-IN-3 (compound 17) is a Wnt/β-catenin inhibitor with low micromolarGI50s against various cancer cells. Wnt/β-catenin-IN-3triggers G2/M cell cycle arrest though activation of p53-p21 pathway as well as intrinsic and extrinsic apoptotic death of colon cancer cells .
    Wnt/β-catenin-IN-3
  • HY-N0636
    Eriocitrin
    1 Publications Verification

    		 Apoptosis Cancer
    Eriocitrin is a flavonoid isolated from lemons that is a powerful antioxidant. Eriocitrin inhibits the proliferation of liver cancer cells by arresting the cell cycle in the S phase by upregulating p53, cyclin A, cyclin D3 and CDK6. Eriocitrin triggers apoptosis by activating intrinsic signaling pathways involving mitochondria .
    Eriocitrin
  • HY-Y0148
    10-Hydroxydecanoic acid

    NSC 15139; 10-HDAA

    		 Parasite Autophagy NF-κB Interleukin Related NO Synthase MDM-2/p53 TNF Receptor RANKL/RANK Caspase Infection Neurological Disease Inflammation/Immunology
    10-Hydroxydecanoic acid (10-HDAA) is a saturated fatty acid derived from 10-hydroxy-trans-2-decenoic acid, which can be isolated from royal jelly. 10-Hydroxydecanoic acid exhibits various biological activities, including anti-inflammatory, insecticidal, anti-malarial, and anti-Leishmania properties, as well as enhancing antigen-specific immune responses. The anti-inflammatory effects of 10-Hydroxydecanoic acid are primarily mediated by inhibiting the activation of NF-κB and the translation of interferon regulatory factor 1 (IRF-1), which reduces the production of interleukin 6 (IL-6) and nitric oxide (NO) in inflammatory cells. Additionally, 10-Hydroxydecanoic acid alleviates neuroinflammatory responses through the p53-autophagy pathway and the p53-NLRP3 pathway. Finally, 10-Hydroxydecanoic acid enhances antigen-specific immune responses by promoting the effective uptake of antigens by microfold cells .
    10-Hydroxydecanoic acid
  • HY-145288
    Antitumor agent-36

    		Apoptosis Cancer
    Antitumor agent-36 possesses potent anti-proliferative and anti-metastasis activities. Antitumor agent-36 induces serious DNA damage and further leads to high expression of γ-H2AX and p53. Antitumor agent-36 promotes apoptosis of tumor cells through mitochondrial apoptotic pathway Bcl-2/Bax/caspase3. Antitumor agent-36 significantly improves immune response through restraining the expression of PD-L1 to increase CD3+ and CD8+ T infiltrating cells in tumor tissues .
    Antitumor agent-36
  • HY-145289
    Antitumor agent-37

    		Apoptosis Cancer
    Antitumor agent-37 possesses potent anti-proliferative and anti-metastasis activities. Antitumor agent-37 induces serious DNA damage and further leads to high expression of γ-H2AX and p53. Antitumor agent-37 promotes apoptosis of tumor cells through mitochondrial apoptotic pathway Bcl-2/Bax/caspase3. Antitumor agent-37 significantly improves immune response through restraining the expression of PD-L1 to increase CD3+ and CD8+ T infiltrating cells in tumor tissues .
    Antitumor agent-37
  • HY-N0292R
    Oleuropein (Standard)

    		Cytochrome P450 PPAR Apoptosis Cardiovascular Disease Inflammation/Immunology Cancer
    Oleuropein (Standard) is the analytical standard of Oleuropein. This product is intended for research and analytical applications. Oleuropein, found in olive leaves and oil, exerts antioxidant, anti-inflammatory and anti-atherogenic effects through direct inhibition of PPARγ transcriptional activity . Oleuropein induces apoptosis in breast cancer cells via the p53-dependent pathway and through the regulation of Bax and Bcl2 genes. Oleuropein also inhibits aromatase .
    Oleuropein (Standard)
  • HY-100035
    PT-262

    		ROCK ERK CDK Apoptosis Cancer
    PT-262 is a potent ROCK inhibitor with an IC50 value of around 5 μM. PT-262 induces the loss of mitochondrial membrane potential and elevates the caspase-3 activation and apoptosis. PT-262 inhibits the ERK and CDC2 phosphorylation via a p53-independent pathway. PT-262 blocks cytoskeleton function and cell migration. PT-262 has anti-cancer activity .
    PT-262
  • HY-117857
    MRT00033659

    		Casein Kinase Checkpoint Kinase (Chk) MDM-2/p53 Early 2 Factor (E2F) Cancer
    MRT00033659 is a potent broad-spectrum kinase inhibitor of CK1 (IC50=0.9 µM for CK1δ) and CHK1 (IC50=0.23 µM). MRT00033659, a pyrazolo-pyridine analogue, induces p53 pathway activation and E2F-1 destabilisation .
    MRT00033659
  • HY-135899
    SIRT7 inhibitor 97491
    3 Publications Verification

    		 Sirtuin Apoptosis Cancer
    SIRT7 inhibitor 97491, a potent SIRT7 inhibitor with an IC50 of 325 nM, reduces deacetylase activity of SIRT7 in a dose-dependent manner. SIRT7 inhibitor 97491 prevents tumor progression by increasing p53 stability through acetylation at K373/382. SIRT7 inhibitor 97491 promotes apoptosis through caspase pathway. .
    SIRT7 inhibitor 97491
  • HY-119948
    AKCI

    		Cyclin G-associated Kinase (GAK) MDM-2/p53 Cancer
    AKCI is a type of AURKC-IκBα interaction inhibitor, with an IC50 value of 24.9 μM. In MDA-MB-231 cells, AKCI can induce G2/M cell cycle arrest by regulating the p53/p21/CDC2/cyclin B1 pathway, inhibit cell migration and invasion, and reduce colony formation and tumor growth. AKCI can be used for research on breast cancer .
    AKCI
  • HY-146516
    Anticancer agent 42

    		MDM-2/p53 Apoptosis Reactive Oxygen Species Cancer
    Anticancer agent 42 (compound 10d) is an orally active anticancer agent, and shows a potent antitumor activity against MDA-MB-231 cell with an IC50 of 0.07 μM. Anticancer agent 42 can exert its anticancer activity by activating apoptotic pathway and p53 expression. Anticancer agent 42 can be used to study metastatic breast cancer .
    Anticancer agent 42
  • HY-N0636R
    Eriocitrin (Standard)

    		Apoptosis Cancer
    Eriocitrin (Standard) is the analytical standard of Eriocitrin. This product is intended for research and analytical applications. Eriocitrin is a flavonoid isolated from lemons that is a powerful antioxidant. Eriocitrin inhibits the proliferation of liver cancer cells by arresting the cell cycle in the S phase by upregulating p53, cyclin A, cyclin D3 and CDK6. Eriocitrin triggers apoptosis by activating intrinsic signaling pathways involving mitochondria .
    Eriocitrin (Standard)
  • HY-113853
    WF-10129

    		Others Others
    WF-10129 is a cytotoxic steroid compound isolated from the genus Physalis. It has the activity of inhibiting the proliferation of liver cancer cells in vitro and in vivo, inducing apoptosis-related biochemical events, interfering with metabolic patterns and significantly reducing lactate production. It can also exert anti-tumor effects by regulating the expression of related genes and proteins through the Akt-p53 pathway.
    WF-10129
  • HY-115924
    CDK1-IN-1

    		CDK Cancer
    CDK1-IN-1 is a potent CDK1 inhibitor (CDK1/CycB IC50=161.2 nM) with potential antiproliferative activity and selectivity for cancer tissues. CDK1-IN-1 induces apoptosis in p53 dependent manner through the intrinsic apoptotic pathway. CDK1-IN-1 is a potential targeted antitumor agent .
    CDK1-IN-1
  • HY-124284
    Hexamethylene bisacetamide

    HMBA

    		 Apoptosis p38 MAPK Akt NF-κB Notch Bcl-2 Family MDM-2/p53 Epigenetic Reader Domain Neurological Disease Metabolic Disease Cancer
    Hexamethylene bisacetamide (HMBA) is a differentiation inducer and selective bromine domain inhibitor that can differentiate across the blood-brain barrier. Hexamethylene bisacetamide can induce tumor cell differentiation and inhibit cell proliferation, showing antitumor activity. Hexamethylene bisacetamide induces apoptosis by Notch1, Bcl-2 and p53 signaling pathways. In addition, Hexamethylene bisacetamide improves the obesity phenotype of mice .
    Hexamethylene bisacetamide
  • HY-118912
    BMH-9

    		Orphan Receptor Others Inflammation/Immunology Cancer
    BMH-9 (Compound Z54) is a modulator for nuclear receptor subfamily 2, group F, member 6 (NR2F6) (also known as nuclear orphan receptor Ear2) . BMH-9 is an activator for p53 signaling pathway through interaction with DNA. BMH-9 inhibits proliferation of human cancer cells, exhibits antitumor efficacy in NOD-SCID mouse models .
    BMH-9
  • HY-143241
    HDAC-IN-34

    		HDAC MDM-2/p53 Apoptosis Cancer
    HDAC-IN-34 (compound 27) is a potent HDAC inhibitor, with IC50 values of 0.022 and 0.45 μM for HDAC1 and HDAC6, respectively. HDAC-IN-34 can bind to DNA and cause DNA damage. HDAC-IN-34 causes cells apoptosis through p53 signaling pathway. HDAC-IN-34 exhibits significant anti-proliferation effect against HCT-116 cells, with an IC50 of 1.41 μM .
    HDAC-IN-34
  • HY-10412
    CEP-1347

    KT7515

    		 JNK Mixed Lineage Kinase MDM-2/p53 Neurological Disease
    CEP-1347 is an inhibitor of the JNK/SAPK pathway with neuroprotective effects. CEP-1347 blocks JNK1 activation induced by members of the mixed lineage kinase (MLK) family (MLK3, MLK2, MLK1, dual leucine zipper kinase, and leucine zipper kinase). As an inhibitor of MDM4, CEP-1347 can more effectively inhibit the growth of glioma cells expressing wild-type p53 .
    CEP-1347
  • HY-160489
    PTK7/β-catenin-IN-2

    		β-catenin Cancer
    PTK7/β-catenin-IN-2 (compound 04967) is an inhibitor of PTK7/β-catenin. It inhibits the binding of PTK7 to β-catenin (IC50: 5.6 μM), thereby inhibiting the signaling of the Wnt/β-catenin pathway. PTK7/β-catenin-IN-2 targets cell growth dependent on the Wnt signaling pathway and has anticancer properties. PTK7/β-catenin-IN-2 also showed inhibitory potency against p53 and MDM2 binding with an IC50 of 157.1 μM .
    PTK7/β-catenin-IN-2
  • HY-146432
    Antitumor agent-60

    		Apoptosis Raf Ras ROS Kinase MDM-2/p53 Cancer
    Antitumor agent-60 (compound 20) is a potent antitumor agent, targeting RAS-RAF signaling pathway and binding to CRAF with a Kd value of 3.93 μM. Antitumor agent-60 induces apoptosis by blocking cell cycle at G2/M phase. Antitumor agent-60 enhances the level of p53 and ROS. Antitumor agent-60 causes oval and irregular nucleus in cancer cells. Antitumor agent-60 can suppress the growth of tumor to some extent in A549 xenograft model .
    Antitumor agent-60
  • HY-161852
    PI3K-IN-55

    		PI3K Apoptosis Cancer
    PI3K-IN-55 (Compound 6a) is a potent inhibitor for PI3K. PI3K-IN-55 affects PI3K/Akt/p53 signaling pathway, inhibits the proliferation of cancer cells A549, Hela, HepG2, MCF-7 and HT-29, with IC50s of 1.03-6.78 μM. PI3K-IN-55 induces apoptosis in cell MCF-7 .
    PI3K-IN-55

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: